Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer

Author:

Lin Yansong123,Qin Shukui4,Li Zhiyong5,Yang Hui6,Fu Wei7,Li Shaohua8,Chen Wenxin9,Gao Zairong10,Miao Weibing11,Xu Huiqin12,Zhang Qing13,Zhao Xinming14,Bao Jiandong15,Li Linfa16,Ren Yuan17,Lin Chenghe18,Jing Shanghua19,Ma Qingjie20,Liang Jun21,Chen Guang22,Zhang Hong23,Zhang Yifan24,Zhou Xianfeng25,Sang Yaxiong25,Hou Zhiguo25

Affiliation:

1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, China

2. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China

3. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

4. Department of Medical Oncology, Cancer Center of Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China

5. Department of Nuclear Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

6. Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

7. Department of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, China

8. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing, China

9. Department of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, China

10. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

11. Department of Nuclear Medicine, Fujian Provincial Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

12. Department of Nuclear Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China

13. Department of Nuclear Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China

14. Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

15. Department of Endocrinology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, China

16. Department of Nuclear Medicine, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, China

17. Department of Nuclear Medicine, Shanxi Provincial Cancer Hospital, Taiyuan, China

18. Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China

19. Department of Otolaryngology-Head and Neck Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

20. Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, China

21. Department of Oncology, Peking University International Hospital, Beijing, China

22. Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, China

23. Department of Nuclear Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

24. Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

25. Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3